My final post before admin approval: warning, it's a long one.
Here's some very informed investment advice re: LNGYZ and LNGZZ. I've owned both since they were originally issued from the buyout of Metabasis Therapeutics by LGND in 2010, of which I was a shareholder. LNGZZ is a cvr targeted to the development of one specific drug (TRBeta) or "Thyroid Receptor. LNGYZ is targeted for "multiple" drug dev. programs including the FBPase inhibitor, that's why it's designated as the "General" cvr because it enompasses mostly all of the remaining Metabasis drug dev. programs. Both (LNGYZ and LNGZZ) have programs licensed to Viking Pharm. (VKTX) by Ligand, by which LGND, LGNYZ and LGNZZ will all receive future milestone and royalty payments as these drugs progress to marketing (Please refer to the "Royalty Table" on Ligand's website). Now the following is a tremendous value proposition imo, that may serve you well if you take the time to research it more thoroughly. When LGNZZ's TRBeta drug prog. went into phase 2 in 2018, the cvr price jumped from .01 to .26/sh within the next couple of months, and still hovers around .23 today, imagine what it will be going into phase 3? And that's not counting any milestone payments. But GUESS WHAT? LNGYZ's drug FBPase Inhibitor is also in phase 2 (again, please refer to the "royalty table" on LGND's website) but it was missed by investors and the price lanquished sub 1 penny. Yet nothing has changed in terms of its value, "especially" when compared to LGNZZ. Both have Phase 2 drugs, yet one went from .01 to .26/sh, the other (LGNYZ) did not. What's even more compelling, is that LGNYZ has "multiple" drug candidates, whereas LGNZZ only has one. Go figure. Now you have a better understanding about these cvrs and why I've devoted the last 10 yrs analyzing them. Whatever you do, do your own dd and please don't base your investment decisions on ANYTHING on this or any other bd until after you've researched it yourself. Good luck.